During this educational program, new opportunities for optimizing outcomes in cardiorenal disease patients with hyperkalemia are disscussed in three lectures.

This course consists of the following lectures:

• RAAS inhibition in patients with kidney disease: balancing the benefits and risks - Prof. Patrick Rossignol, MD
• Addressing the risk of hyperkalemia: is there a sweet spot for potassium binding? - Prof. Peter van der Meer, MD
• Managing hyperkalemia in cardiorenal patients: Novel therapeutic insights to optimize outcomes - Prof. Matthew Weir, MD

After watching the videos on RAASi and hyperkalemia in cardiorenal disease, the learner should be able to:

• Explain the challenge of following guideline recommended (dose of) RAASi therapy in cardiorenal patients
• Recall the association between serum potassium levels and outcomes
• Describe determinants and prevalence of hyperkalemia in HF
• Explain the unmet need to treat hyperkalemia with older agents
• Name new agents in hyperkalemia management that result in improved outcomes in cardiorenal patients
• Describe details of trials that investigated/are investigating new potassium binders

Expert faculty

• Patrick Rossignol, MD - Nancy, France
• Peter van der Meer, MD - Groningen, The Netherlands
• Matthew Weir, MD - Baltimore, MD, USA

Target audience

This educational activity is designed for cardiologists in secondary care and other healthcare professionals with an interest in treating patients with cardiorenal disease.

CME accreditation

This online course is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit.

Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Vifor Fresenius Medical Care Renal Pharma.